Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MBX with free AI briefings, catalyst countdowns, and dilution alerts.

MBX · MBX Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$482.6M Cash on Hand
50.4mo Cash Runway
Follow MBX by email Get an email when MBX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MBX, unsubscribe in one click. Privacy

📣 What MBX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Canvuparatide Hypoparathyroidism Phase 3 · NCT07699471 Recruiting
200-1600 µg of MBX 2109 once-weekly by… Hypoparathyroidism Phase 2 · NCT06531941 Active not recruiting
400 µg of MBX 2109 once-weekly by subcutaneous… Hypoparathyroidism Phase 2 · NCT06531941 Active not recruiting
MBX 1416 (INN imapextide) Postbariatric Hypoglycemia Phase 2 · NCT07029412 Completed
MBX 2109 Healthy Phase 1 · NCT05158335 Completed
MBX 4291 Obesity Phase 1 · NCT07142707 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MBX holds $482.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $28.7M/quarter from operations, an estimated runway of 50.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 17 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MBX files for a raise →

👥 Who Owns MBX

Insiders 13.4% Other 5%+ holders 14.9% Institutions (261 holders) 71.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 7,224,009 14.55% 2026-09-30
Patrick J Heron
Director, 10% owner · +28,500 options
Insider 5,243,421 10.56% 2026-08-06
Wellington Management Group LLP Institution (13G, 5%+) 4,977,523 10.02% 2026-06-30
Paradigm BioCapital Advisors LP 5%+ holder (13G) 3,772,885 7.60% 2026-09-30
Edward T. Mathers 5%+ holder (13D) 3,619,474 7.29% 2025-11-06
ORBIMED ADVISORS LLC Institution (13G, 5%+) 3,074,853 6.19% 2026-08-06
BlackRock, Inc. Institution (13G, 5%+) 2,628,181 5.29% 2026-06-30
P. Kent Hawryluk
President & CEO, Director · +385,876 options
Insider 1,214,444 2.45% 2026-05-06
Steven L. Hoerter
Chairman, President and CEO, Director · +499,500 options
Insider 98,045 0.20% 2026-11-10
John W Smither
Chief Financial Officer · +130,000 options
Insider 28,000 0.06% 2026-08-03
Ora H. Pescovitz
Director · +28,500 options
Insider 24,329 0.05% 2026-06-04
Richard Bartram
Chief Financial Officer · +70,000 options
Insider 15,000 0.03% 2026-02-02

Share count 49,656,265 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MBX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MBX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.